Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019–2021

被引:1
|
作者
Lian Huimin [1 ]
Jiang Huimin [1 ]
Yi Lina [5 ]
Sun Jing [8 ]
Xie Huaping [11 ]
Qiu Ming [5 ]
Sun Limei [13 ]
Lin Huifang [5 ]
Yang Mingda [5 ]
Qu Lin [5 ]
Yang Haiyi [5 ]
Lu Jing [1 ]
Zeng Hanri [13 ]
机构
[1] Guangzhou Center for Disease Control and Prevention
[2] Guangzhou 510440
[3] Guangdong Workstation for Emerging Infectious Disease Control and Prevention
[4] Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response
[5] School of Public Health
[6] Southern Medical University  3. Guangzhou 510515  4. China
[7] Guangdong Provincial Institution of Public Health
[8] Guangdong Provincial Center for Disease Control and Prevention  7. Guangzhou 511430
[9] Health Commission of Heping District
[10] Shenyang City  10. Liaoning 110003
关键词
Enterovirus A71; Vaccine; Seroepidemiology;
D O I
暂无
中图分类号
R725.1 [小儿传染病];
学科分类号
摘要
Enterovirus A71 (EV-A71) is a significant hand-foot-mouth disease (HFMD) etiology. The inactivated EV-A71 vaccines were approved in China in 2016. However, the seroprevalence of EV-A71 after the vaccine application and its potential association with the EV-A71 epidemic in the population are rarely studied. In this study, we analyzed the incidence of EV-A71 infection and seroepidemiology in Guangzhou City, China. From 2019 to 2021, 167,920 clinically confirmed HFMD cases were reported in Guangzhou. In 6,868 enterovirus-positive samples, Coxsackievirus A6 and Coxsackievirus A16 were dominant genotypes, and only 3 EV-A71-positive samples were detected, highlighting the deficient epidemic activity of EV-A71. Microneutralization assay was performed on 1,000 representative serum samples. Notably, the seroprevalence and geometric mean titer (GMT) decreased significantly in 2020, and that in the < 3-year age group were increased and even higher than that in 3–5-year age group in 2019 and 2021, which was contrary to our previous surveillance result and other studies in Guangzhou. Furthermore, a moderate decline of GMT level was observed following the vaccination, but the seropositive serums were still detected for 49 months after second immunization, suggesting the long-term persistence of the immunity. Our seroepidemiology study revealed relatively higher neutralizing antibody activity in the susceptible population after the EV-A71 vaccine was adopted in 2016 in Guangzhou. It may be one of the reasons for the lower epidemic activity of EV-A71 in Guangzhou from 2019 to 2021.
引用
收藏
相关论文
共 50 条
  • [1] Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019-2021
    Lian, Huimin
    Jiang, Huimin
    Yi, Lina
    Sun, Jing
    Xie, Huaping
    Qiu, Ming
    Sun, Limei
    Lin, Huifang
    Yang, Mingda
    Qu, Lin
    Yang, Haiyi
    Lu, Jing
    Zeng, Hanri
    BIOSAFETY AND HEALTH, 2023, 5 (03) : 168 - 173
  • [3] Recent advances in enterovirus A71 pathogenesis: a focus on fatal human enterovirus A71 infection
    Jingjun Xing
    Ke Wang
    Geng Wang
    Na Li
    Yanru Zhang
    Archives of Virology, 2022, 167 : 2483 - 2501
  • [4] Recent advances in enterovirus A71 pathogenesis: a focus on fatal human enterovirus A71 infection
    Xing, Jingjun
    Wang, Ke
    Wang, Geng
    Li, Na
    Zhang, Yanru
    ARCHIVES OF VIROLOGY, 2022, 167 (12) : 2483 - 2501
  • [5] Seroprevalence of Enterovirus A71 and Coxsackievirus A16 in Healthy People in Shandong Province, China
    Wang, Jian-xing
    Zhu, Shuang-li
    Wang, Jing
    Lin, Yi
    Pei, Yao-wen
    Sun, Da-peng
    Zhang, Yong
    Wang, Xian-jun
    Xu, Wen-bo
    Ding, Shu-jun
    PLOS ONE, 2016, 11 (09):
  • [6] Increased detection of enterovirus A71 infections, Germany, 2019
    Boettcher, Sindy
    Diedrich, Sabine
    Keeren, Kathrin
    Ackermann, Nikolaus
    Adam, Maja
    Baillot, Armin
    Ehrhard, Ingrid
    Enders, Martin
    Hafezi, Wali
    Hahn, Ralph
    Hofmann, Jorg
    Korn, Klaus
    Kuhn, Joachim
    Michel, Detlef
    Pettke, Alexandra
    Prifert, Christiane
    Rabenau, Holger F.
    Reif, Ursula
    Rieder, Gabriele
    Weissbrich, Benedikt
    Wille, Andreas
    Zuchowski, Marta J.
    EUROSURVEILLANCE, 2019, 24 (39): : 2 - 6
  • [7] Enterovirus A71 Vaccines
    Li, Mei-Ling
    Shih, Shin-Ru
    Tolbert, Blanton S.
    Brewer, Gary
    VACCINES, 2021, 9 (03) : 1 - 10
  • [8] Insight into the Enterovirus A71: A review
    Kinobe, Robert
    Wiyatno, Ageng
    Artika, I. Made
    Safari, Dodi
    REVIEWS IN MEDICAL VIROLOGY, 2022, 32 (06)
  • [9] Antivirals and vaccines for Enterovirus A71
    Lin, Jing-Yi
    Kung, Yu-An
    Shih, Shin-Ru
    JOURNAL OF BIOMEDICAL SCIENCE, 2019, 26 (01)
  • [10] Cellular receptors for enterovirus A71
    Kobayashi, Kyousuke
    Koike, Satoshi
    JOURNAL OF BIOMEDICAL SCIENCE, 2020, 27 (01)